Basel biologist wins science prize for thalidomide insights
Structural biologist Nicolas Thomä has been awarded this year’s Otto Naegeli Prize for medical research, considered one of the most prestigious scientific awards in Switzerland.
This content was published on
3 minutes
Keystone-SDA/ts
Español
es
Un biólogo de Basilea gana el premio científico Otto Naegeli
German-born Thomä, from the Friedrich Miescher Institute for Biomedical Research (FMI) in Basel, is particularly concerned in his research with the degradation of disease-causing proteins, the FMI said in a statementExternal link on Tuesday. He and his team showed how some small molecules contribute to targeted protein degradation by functioning as “molecular glues”.
“Such molecular glues have the potential to target proteins that were previously thought to be undruggable,” the FMI wrote.
Every two years, the Otto Naegeli Foundation awards the prizeExternal link to outstanding personalities in medical research. The prize was established in 1960 in memory of the Zurich researcher and lecturer of internal medicine, Otto Naegeli (1871-1938).
Worth CHF200,000, the prize is awarded to researchers in Switzerland with the aim of stimulating medical and biomedical research. It recognises outstanding work on new biological mechanisms of action or therapeutic approaches.
Research from Thomä’s laboratory explained how the molecular glue thalidomide and its analogues function at the molecular level.
From 1957 thalidomide, marketed by West German company Chemie Grünenthal, was used to treat nausea during pregnancy. It gained notoriety at the beginning of the 1960s when it was discovered that it caused birth defects, usually involving babies’ limbs, whereupon it was withdrawn from the market. Later, however, the active ingredient experienced a renaissance in the fight against various forms of blood cancer. This is because thalidomide can mark disease-causing proteins as waste and release them for degradation, which causes the cancer cells to die. This video explains how.
External Content
However, thalidomide can also interact with proteins that are important during embryonic development in the womb, which is probably the cause of the malformations.
New therapeutic drugs
The disclosed mechanism of action of thalidomide is groundbreaking for the next generation of therapeutic drugs, according to Thomä. The findings would also make it possible both to recognise and minimise undesirable side effects of drugs and to attack several disease-causing proteins simultaneously with one drug, he said.
Thomä said he would like to use the CHF200,000 ($210,000) prize money to develop a new generation of drugs based on the molecular glue principle. This is because many proteins behind diseases such as cancer, cardiovascular diseases or diabetes cannot yet be tackled with traditional methods, he explained.
Thomä, 50, has been working at the Friedrich Miescher Institute since 2006. Previously, he conducted research at the University of Cambridge in England, at the Max Planck Institute for Molecular Physiology in Dortmund (Germany) and at the Memorial Sloan Kettering Cancer Center in New York City.
The award ceremony will take place on June 14 at the Biozentrum of the University of Basel.
More
More
The Swiss politician who learnt to live with the effects of thalidomide
This content was published on
Fifty years after a momentous court case over the drug thalidomide, Christian Lohr talks to Swiss public television, SRF. (SRF, swissinfo.ch)
Switzerland condemned for deciding to deport gay Iranian
This content was published on
Switzerland violated the prohibition on inhuman treatment by considering that a gay Iranian could be returned to his country.
Gestational diabetes found to increase risk of adult-onset diabetes
This content was published on
A research team from the Lake Geneva region has identified persistent dysfunctions in glucose regulation in women with gestational diabetes. In the long term, this can increase the risk of adult-onset diabetes by up to ten times.
Swiss village must be evacuated by midday on Sunday
This content was published on
The village of Brienz-Brinzauls in eastern Switzerland, which is threatened by a rockfall, must be evacuated by 1pm on Sunday. All residents must leave the village.
This content was published on
A former judge of the Graubünden Administrative Court in eastern Switzerland has been found guilty of rape, sexual harassment and threatening a former trainee.
Costs and care time increase in Swiss retirement and nursing homes
This content was published on
In 2023 the costs of retirement and nursing homes increased by 5% compared to 2022 and those of assistance and care at home by 7%. Together, they amounted to CHF15 billion.
This content was published on
Almost half of the population in Switzerland shows clear to pronounced signs of smartphone addiction, according to a survey.
Swiss healthcare stakeholders want to save CHF300 million
This content was published on
The main players in the Swiss healthcare sector want to save around CHF300 million ($340 million) in healthcare costs a year from 2026.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
The women changing science in Switzerland
This content was published on
For the international day of women in science, four portraits of women who are changing the face of research in Switzerland.
Ukraine war threatens to derail development of new cancer treatments
This content was published on
The war in Ukraine could disrupt hundreds of clinical trials for critical cancer drugs, many of which are being developed by companies in Switzerland.
How the Swiss-based WHO BioHub is preparing for future pandemics
This content was published on
The first WHO BioHub facility, aimed at storing, analysing and quickly sharing viruses and pathogens, will be based at the Spiez lab near Bern.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.